Project Details
Description
The following studies will be part of this PhD project.
1. In this study, the researchers aimed to analyze the levels of neutrophil extracellular traps (NET markers), including the primary marker H3Cit and secondary markers NE, cfDNA, and IL-8, in the plasma of 200 patients with ovarian tumors of varying degrees of malignancy (benign, borderline, and malignant). The objective of the study was to investigate whether H3Cit could discriminate between malignant and benign ovarian tumors. The researchers collected plasma samples from the patients and performed analyses to measure the levels of the NET markers. The results of the study could provide valuable insights into the use of H3Cit as a potential biomarker for differentiating between benign and malignant ovarian tumors. The study highlights the importance of further research in this area to improve ovarian cancer diagnosis and treatment.
2. This study aimed to assess the levels of circulating tumor DNA (ctDNA) in the blood of ovarian cancer patients before surgery and correlate it with patient outcomes and clinical features. The researchers extracted tumor DNA from 41 ovarian cancer patients and used targeted sequencing to identify somatic mutations in the tumor DNA. They then used digital PCR assays to measure ctDNA levels in patient plasma samples. The results of the study could help in the development of minimally invasive cancer diagnostic and monitoring methods. The study highlights the potential of ctDNA as a promising biomarker for ovarian cancer diagnosis and management.
3. This study aims to analyze protein panels that could predict prognosis in patients with pelvic tumors, specifically ovarian, tubal, and peritoneal cancers. The researchers will use Olink® Multiplex assays, which measure changes in protein levels between populations and generate Normalized Protein eXpression (NPX) units for statistical analysis. The NPX values will be compared between samples for each assay. The study will test different biomarker panels to determine their effectiveness in predicting patient prognosis. The results of the study could help improve treatment outcomes for patients with ovarian, tubal, and peritoneal cancers.
1. In this study, the researchers aimed to analyze the levels of neutrophil extracellular traps (NET markers), including the primary marker H3Cit and secondary markers NE, cfDNA, and IL-8, in the plasma of 200 patients with ovarian tumors of varying degrees of malignancy (benign, borderline, and malignant). The objective of the study was to investigate whether H3Cit could discriminate between malignant and benign ovarian tumors. The researchers collected plasma samples from the patients and performed analyses to measure the levels of the NET markers. The results of the study could provide valuable insights into the use of H3Cit as a potential biomarker for differentiating between benign and malignant ovarian tumors. The study highlights the importance of further research in this area to improve ovarian cancer diagnosis and treatment.
2. This study aimed to assess the levels of circulating tumor DNA (ctDNA) in the blood of ovarian cancer patients before surgery and correlate it with patient outcomes and clinical features. The researchers extracted tumor DNA from 41 ovarian cancer patients and used targeted sequencing to identify somatic mutations in the tumor DNA. They then used digital PCR assays to measure ctDNA levels in patient plasma samples. The results of the study could help in the development of minimally invasive cancer diagnostic and monitoring methods. The study highlights the potential of ctDNA as a promising biomarker for ovarian cancer diagnosis and management.
3. This study aims to analyze protein panels that could predict prognosis in patients with pelvic tumors, specifically ovarian, tubal, and peritoneal cancers. The researchers will use Olink® Multiplex assays, which measure changes in protein levels between populations and generate Normalized Protein eXpression (NPX) units for statistical analysis. The NPX values will be compared between samples for each assay. The study will test different biomarker panels to determine their effectiveness in predicting patient prognosis. The results of the study could help improve treatment outcomes for patients with ovarian, tubal, and peritoneal cancers.
| Status | Active |
|---|---|
| Effective start/end date | 2018/12/01 → … |
Subject classification (UKÄ)
- Cancer and Oncology
- Gynaecology, Obstetrics and Reproductive Medicine